Establishing MRSI as a Clinical Standard Imaging

Glioblastomas (GBM) are the most prevalent malignant primary brain tumors in adults. Given the infiltrative nature of GBMs, an imaging modality more capable of identifying the extent of tumor infiltration would prove beneficial in disease targeting to prevent recurrences. MR spectroscopic imaging (MRSI) is a molecular imaging technique that measures endogenous metabolite levels without any contrast agent. sMRI holds tremendous promise as a molecular imaging modality. However, it has yet to be adopted in clinical settings, largely due to challenges in image processing and interpretation of 3D GRAPPA-EPSI data. With the development of BrICS and advanced image processing techniques, the authors seek to make sMRI a clinical standard in imaging.